Nuvation Bio (NUVB) Change in Accured Expenses (2020 - 2026)

Nuvation Bio (NUVB) has reported Change in Accured Expenses for 7 consecutive years, with -$12.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 37.78% year-over-year to -$12.3 million; the TTM figure through Mar 2026 stood at $9.0 million (up 348.33% YoY), while the FY2025 annual figure was $12.4 million, up 80.61% from the prior year.
• Change in Accured Expenses eased to -$12.3 million in Q1 2026 per NUVB's latest filing, from $12.6 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $12.6 million in Q4 2025 and bottomed at -$12.3 million in Q1 2026.
• Historically, Change in Accured Expenses has averaged $266176.5 across 5 years, with a median of $483000.0 in 2022.
• Annual changes were most pronounced in 2023 — Change in Accured Expenses sank 1962.0% — and 2024, when it jumped 455.38%.
• Nuvation Bio's Change in Accured Expenses stood at -$100000.0 in 2022, then tumbled by 1962.0% to -$2.1 million in 2023, then surged by 455.38% to $7.3 million in 2024, then surged by 72.0% to $12.6 million in 2025, then plunged by 197.74% to -$12.3 million in 2026.
• Business Quant data shows NUVB's Change in Accured Expenses at -$12.3 million in Q1 2026, $12.6 million in Q4 2025, and $8.6 million in Q3 2025.